Aliases & Classifications for Cystadenoma

MalaCards integrated aliases for Cystadenoma:

Name: Cystadenoma 12 54 44 15 70
Craniopharyngioma 70
Cystoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2634
MeSH 44 D003537
NCIt 50 C2972
SNOMED-CT 67 189680006
UMLS 70 C0010276 C0010633

Summaries for Cystadenoma

Disease Ontology : 12 An adenoma that forms a cyst.

MalaCards based summary : Cystadenoma, also known as craniopharyngioma, is related to mucinous ovarian cystadenoma and hidrocystoma, and has symptoms including visual disturbance An important gene associated with Cystadenoma is KRT7 (Keratin 7), and among its related pathways/superpathways are CLEC7A (Dectin-1) signaling and O-linked glycosylation. The drugs Prednisone and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include pancreas, ovary and appendix, and related phenotype is Decreased sensitivity to paclitaxel.

Wikipedia : 73 Cystadenoma (or "cystoma") is a type of cystic adenoma. When malignant, it is called... more...

Related Diseases for Cystadenoma

Diseases related to Cystadenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 813)
# Related Disease Score Top Affiliating Genes
1 mucinous ovarian cystadenoma 32.5 KRT7 KRT20 CEACAM5
2 hidrocystoma 32.4 KRT7 CEACAM5
3 pancreatic serous cystadenoma 32.2 MUC6 CHGA CEACAM5
4 ovarian cystadenoma 32.1 MUC16 KRT7 CEACAM5 BRCA1
5 ovarian serous cystadenocarcinoma 32.1 SERPINA3 PGR MUC16 CEACAM5
6 pancreatic cystadenoma 31.9 SYP CHGA CEACAM5
7 appendix adenocarcinoma 31.5 SYP KRT7 KRT20 CHGA
8 pancreatic mucinous cystadenoma 31.4 PGR MUC5AC MUC1 MME KRT7 KRT20
9 microcystic adenoma 30.9 VHL SYP SERPINA3 MUC6 MUC1 INHA
10 cystadenocarcinoma 30.8 SERPINA3 PGR MUC5AC MUC16 MUC1 KRT7
11 pseudo-meigs syndrome 30.6 MUC16 CALB2
12 mucinous cystadenocarcinoma 30.5 MUC16 MUC1 KRT7 KRT20 CEACAM5 CEACAM3
13 hydrocele 30.4 KRT7 CALB2 AFP
14 fibroma 30.4 SERPINA3 MUC16 CALB2
15 endometriosis 30.4 PTEN PGR MUC16 CALB2
16 adenomatoid tumor 30.4 KRT7 CALB2 AFP
17 leiomyosarcoma 30.4 SERPINA3 PGR MUC1
18 bile duct cystadenocarcinoma 30.3 MUC6 MUC5AC MUC1 KRT7 CEACAM5 AFP
19 adenocarcinoma 30.3 PTEN MUC1 KRT7 KRT20 CEACAM5 BRCA1
20 spindle cell sarcoma 30.3 SERPINA3 MUC1 KRT7
21 pleomorphic lipoma 30.3 SERPINA3 PGR
22 ovarian germ cell teratoma 30.3 SYP KRT7 CALB2 AFP
23 intravenous leiomyomatosis 30.2 PGR MME
24 cystic teratoma 30.2 SYP PTEN MUC6 MUC5AC KRT7 KRT20
25 mucocele of appendix 30.2 PGR MME CEACAM5
26 leiomyomatosis 30.2 VHL PGR CALB2
27 adenoma 30.2 VHL SYP MUC6 MUC5AC MUC1 KRT7
28 goblet cell carcinoid 30.2 KRT20 CHGA
29 intestinal obstruction 30.2 KRT7 KRT20 CEACAM5
30 ovarian clear cell carcinoma 30.2 PTEN MUC16 KRT7
31 renal cell carcinoma, nonpapillary 30.2 VHL PTEN MUC1 MME KRT7 KRT20
32 ectopic pregnancy 30.1 PGR MUC1 AFP
33 bile duct cysts 30.1 KRT7 CEACAM5 AFP
34 spermatocele 30.1 CALB2 AFP
35 neurilemmoma 30.1 SERPINA3 MUC1 CALB2
36 mature teratoma 30.1 SYP KRT7 CEACAM5 AFP
37 hidradenoma 30.1 MUC1 MME KRT7 CEACAM5
38 adenosarcoma 30.1 SERPINA3 PGR MME
39 supine hypotensive syndrome 30.1 KRT7 KRT20
40 pseudomyxoma peritonei 30.1 REG4 MUC6 MUC5AC MUC16 MUC1 KRT7
41 oncocytoma 30.1 VHL SYP MUC1 MME KRT7 KRT20
42 serous cystadenocarcinoma 30.1 PTEN PGR MUC16 BRCA1
43 ovarian mucinous neoplasm 30.1 MUC6 MUC5AC KRT7 KRT20 CEACAM5
44 cystadenofibroma 30.1 MUC16 MUC1 MME KRT7 INHA CALB2
45 endosalpingiosis 30.1 PGR MUC1 KRT7 CALB2 BRCA1
46 syringocystadenoma papilliferum 30.0 SERPINA3 MUC1
47 clear cell papillary renal cell carcinoma 30.0 VHL MME KRT7
48 leydig cell tumor 30.0 SYP INHA CALB2 AFP
49 angiomyolipoma 30.0 PGR MME KRT7
50 benign mesothelioma 30.0 KRT7 KRT20 CEACAM5 CALB2

Graphical network of the top 20 diseases related to Cystadenoma:



Diseases related to Cystadenoma

Symptoms & Phenotypes for Cystadenoma

UMLS symptoms related to Cystadenoma:


visual disturbance

GenomeRNAi Phenotypes related to Cystadenoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased sensitivity to paclitaxel GR00112-A-0 8.32 PTEN

Drugs & Therapeutics for Cystadenoma

Drugs for Cystadenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
4 Hormones Phase 4
5 Hormone Antagonists Phase 4
6 Antineoplastic Agents, Hormonal Phase 4
7 glucocorticoids Phase 4
8 Anti-Inflammatory Agents Phase 4
9 Anesthetics Phase 4
10 Hydrocortisone 17-butyrate 21-propionate Phase 4
11 Hydrocortisone hemisuccinate Phase 4
12
Ethanol Approved Phase 2, Phase 3 64-17-5 702
13
Glucagon Approved Phase 3 16941-32-5
14
Exenatide Approved, Investigational Phase 3 141758-74-9 15991534
15
Diazoxide Approved Phase 3 364-98-7 3019
16 Anti-Infective Agents, Local Phase 2, Phase 3
17 Glucagon-Like Peptide 1 Phase 3
18 Incretins Phase 3
19 Anti-Obesity Agents Phase 3
20 Hypoglycemic Agents Phase 3
21 Vasodilator Agents Phase 3
22 Antihypertensive Agents Phase 3
23
Metformin Approved Phase 2 657-24-9 4091 14219
24
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
25
Vemurafenib Approved Phase 2 918504-65-1 42611257 23252090
26
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
27
Memantine Approved, Investigational Phase 2 19982-08-2 4054
28
Oxytocin Approved, Vet_approved Phase 2 50-56-6 53477758 439302
29
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
30
Methionine Approved, Nutraceutical Phase 2 63-68-3 6137
31 insulin Phase 2
32 Insulin, Globin Zinc Phase 2
33 Angiogenesis Inhibitors Phase 2
34 topoisomerase I inhibitors Phase 2
35 CKD732 Phase 2
36 Protein Kinase Inhibitors Phase 2
37 Dopamine Agents Phase 2
38 Excitatory Amino Acid Antagonists Phase 2
39 Neurotransmitter Agents Phase 2
40 Antiparkinson Agents Phase 2
41 Fluorodeoxyglucose F18 Phase 2
42 Anti-Infective Agents Phase 2
43 Antiviral Agents Phase 2
44
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
45
Temozolomide Approved, Investigational Phase 1 85622-93-1 5394
46
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
47
Lenalidomide Approved Phase 1 191732-72-6 216326
48
Lenograstim Approved, Investigational Phase 1 135968-09-1
49
Bortezomib Approved, Investigational Phase 1 179324-69-7 93860 387447
50
Pancrelipase Approved, Investigational Phase 1 53608-75-6

Interventional clinical trials:

(show top 50) (show all 55)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
3 EUS-Guided Pancreatic Injection of Cyst (EPIC) Trial Completed NCT00233038 Phase 2, Phase 3
4 Multicentre Double-blind Randomized Clinical Trial Assessing Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Completed NCT02860923 Phase 3 Exenatide;Placebo
5 Clinical Assessment of the Treatment With Diazoxide in Children Suffering From Obesity and Hyperinsulinemia Secondary to Surgery of Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3 DIAZOXIDE
6 Combined Diazoxide and Metformin Therapy in Children With Hypothalamic Obesity Secondary to Craniopharyngioma: A Pilot Study Completed NCT00892073 Phase 2 Diazoxide;Metformin
7 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
8 Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity Completed NCT01484873 Phase 2 Exenatide
9 Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension Completed NCT02063295 Phase 2 ZGN-440 sterile diluent;ZGN-440 for injectable suspension
10 A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection Recruiting NCT02792582 Phase 2
11 Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas Recruiting NCT03224767 Phase 2 Vemurafenib;Cobimetinib
12 Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study Recruiting NCT03194906 Phase 2 Memantine
13 Methionine PET/CT Studies In Patients With Cancer Recruiting NCT00840047 Phase 2 Methionine
14 Intranasal Oxytocin to Promote Weight Loss in Children, Adolescents, and Adults With Brain Tumors and Hypothalamic Obesity Syndrome Active, not recruiting NCT02849743 Phase 2 Syntocinon;Placebo (for Syntocinon)
15 Phase II Study on the Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy Active, not recruiting NCT02842723 Phase 2
16 A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection Active, not recruiting NCT01419067 Phase 2 ^1^8F-fluorodeoxyglucose;^1^1C-methionine
17 A Phase II Study of Image-Guided Radiation Therapy for Pediatric CNS Tumors and Quantification of Radiation-Related CNS Effects Active, not recruiting NCT00187226 Phase 2
18 A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System Not yet recruiting NCT04743310 Phase 2 tozuleristide
19 Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma Terminated NCT01964300 Phase 2
20 A PHASE 1 STUDY OF ISPINESIB (SB-715992) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS Completed NCT00363272 Phase 1 ispinesib
21 A PHASE I STUDY OF DEPSIPEPTIDE (NSC#630176, IND# 51810) IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS AND LEUKEMIAS Completed NCT00053963 Phase 1 romidepsin
22 A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
23 A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients With Recurrent or Refractory Primary CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
24 Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
25 Phase I Pilot Study of Stereotaxic Radiosurgery in Patients With Intracranial Neoplasms Completed NCT00019578 Phase 1
26 Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
27 Phase I Study of Cilengitide (EMD 121974) in Children With Refractory Brain Tumors Completed NCT00063973 Phase 1 cilengitide
28 A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
29 A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas Completed NCT00994500 Phase 1 vorinostat;bortezomib
30 Phase I Feasibility Trial To Study The Safety Of Sealing Resected Pancreatic Surfaces After Partial Distal Pancreatectomy Using Laser Tissue Welding Recruiting NCT03147768 Phase 1
31 EUS Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm Terminated NCT01525706 Phase 1 Ethanol and Paclitaxel Injection
32 Microenvironment: Imaging/Implications in Brain Tumors; A Preliminary Investigation of the Biodistribution of [F-18]-EF5 in Patients With Brain Tumors Terminated NCT00110032 Phase 1 EF5
33 A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
34 Diagnosis of Pancreatic Cystic Lesions With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy Unknown status NCT03884179
35 Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma Unknown status NCT00949156
36 A Phase II MULTICENTRE Trial of Needle Based Laser Confocal Endomicroscopy of Cystic and Solid Tumours of the Pancreas Completed NCT02523170
37 Intraoperative Use of a MR Tomography System Combined With Neuronavigation - Analysis of the Craniopharyngioma Subgroup ("Intraoperative Nutzung Eines Kernspintomographie-Systems in Direkter Kopplung Mit Einem Neuronavigations-System") Completed NCT01206543
38 Social Participation After Childhood Craniopharyngioma Completed NCT03139526
39 Examining Sleep and Family Functioning in Pediatric Craniopharyngioma Using Ecological Momentary Assessment Completed NCT03330080
40 Weight Gain in Surgically Treated Adult-onset Craniopharyngioma Completed NCT01968603
41 KRANIOPHARYNGEOM 2007 - Multicenter Prospective Study of Children and Adolescents With Craniopharyngioma Completed NCT01272622
42 Prospective, Multi-Center Survey Study of Children and Adolescents With Craniopharyngioma Completed NCT00258453
43 Cross Sectional Study of Sleep-wake and Melatonin Patterns in Patients Treated for Craniopharyngiomas Compared to Matched Controls Completed NCT01881854
44 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens Completed NCT00919750
45 Study of Feasibility and Diagnostic Profitability of Intra-cyst Fluid Molecular Biology Analysis in Pancreatic Cyst Tumors. Recruiting NCT03305146
46 Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts Recruiting NCT01643460
47 A Phase 0/Feasibility Trial of Tocilizumab in Children and Adolescents With Newly- Diagnosed or Recurrent/Progressive Adamantinomatous Craniopharyngioma Recruiting NCT03970226 Early Phase 1 Tocilizumab
48 KRANIOPHARYNGEOM Registry 2019 Multicenter Registry for Patients With Childhood-onset Craniopharyngioma, Xanthogranuloma, Cysts of Rathke's Pouch, Meningioma, Pituitary Adenoma, Arachnoid Cysts Recruiting NCT04158284
49 Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology Recruiting NCT04648462
50 A Prospective Longitudinal Quality of Life Study in Patients Undergoing Endoscopic Endonasal Skull Base Surgery Recruiting NCT04087902

Search NIH Clinical Center for Cystadenoma

Cochrane evidence based reviews: cystadenoma

Genetic Tests for Cystadenoma

Anatomical Context for Cystadenoma

MalaCards organs/tissues related to Cystadenoma:

40
Pancreas, Ovary, Appendix, Liver, Salivary Gland, Prostate, Thyroid

Publications for Cystadenoma

Articles related to Cystadenoma:

(show top 50) (show all 3906)
# Title Authors PMID Year
1
Role of cystic fluid in diagnosis of the pancreatic cystadenoma and cystadenocarcinoma. 61 54
18251127 2007
2
Expression of estrogen and progesterone receptors and inhibin-alpha in hepatobiliary cystadenoma: an immunohistochemical study. 54 61
17457606 2007
3
Epididymal cystadenomas and epithelial tumourlets: effects of VHL deficiency on the human epididymis. 61 54
16841375 2006
4
Expression of glycodelin in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastases. 61 54
16033096 2005
5
Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. 54 61
15466181 2004
6
Value of inhibin staining in gynecological pathology. 61 54
11192074 2001
7
Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. 54 61
10620446 2000
8
Expression of glycodelin in MCF-7 breast cancer cells induces differentiation into organized acinar epithelium. 61 54
9426393 1997
9
Von Hippel-Lindau syndrome. 54 61
7670659 1995
10
Pancreatobiliary manifestations of nonalcoholic fatty liver disease: a retrospective case-control multicenter study. 61
32483086 2021
11
Multifocal giant apocrine cystadenomas in a miniature poodle. 61
33231333 2021
12
Mis-diagnosed giant ovarian cyst and ventriculoperitoneal shunt malfunction. 61
33166567 2021
13
Paratesticular Papillary Cystadenoma of the Epididymis in the Setting of von Hippel-Lindau. 61
33673939 2021
14
Calponin and MUC6 complement inhibin as diagnostic immunomarkers of serous cystadenoma in endoscopic ultrasound guided aspiration/biopsy specimens. 61
33657658 2021
15
Seminal Vesicle Cystadenoma with Dysplasia: Missing Link to Adenocarcinoma? 61
33783025 2021
16
Ovarian mucinous cystadenoma causing acute urinary retention. 61
33665854 2021
17
Ovarian seromucinous tumors: clinicopathological features of 10 cases with a detailed review of the literature. 61
33736662 2021
18
Comprehensive immunohistochemical analysis of the gastrointestinal and Müllerian phenotypes of 139 ovarian mucinous cystadenomas. 61
33275953 2021
19
Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma. 61
33788752 2021
20
Added value of [68Ga]Ga-DOTA-TOC PET/CT for characterizing pancreatic neuroendocrine neoplasms: a comparison with contrast-enhanced CT and/or MRI in a large study cohort. 61
33787974 2021
21
Herlyn-Werner-Wunderlich syndrome with borderline serous cystadenoma of the ovary: case report and literature review. 61
33532015 2021
22
A mixed Müllerian cystadenoma presenting as a paraurethral tumor. 61
33364289 2021
23
A Huge Ovarian Mucinous Cystadenoma in a 15-Year-Old Girl with Situs Inversus Totalis: Report of a Rare Case. 61
32688052 2021
24
Metachronous Contralateral Cystadenoma After Ovariectomy for Juvenile Granulosa Cell Tumor in a Young Girl: An Uncommon Association. 61
32745618 2021
25
Borderline Brenner Tumor of the Ovary Coexisting With an Ovarian Mucinous Cystadenoma With Focal Atypical Epithelial Proliferation: A Rare Case With Review of the Literature. 61
33635096 2021
26
Prostatic cystadenoma. A case-report illustrating diagnosis and surgical management of an unusual condition. 61
33356753 2021
27
Identification and analysis of RNA editing events in ovarian serous cystadenoma using RNA-seq Data. 61
33573552 2021
28
Two Port Laparoscopic Removal of Large Ovarian Cystadenoma. 61
33631322 2021
29
Spontaneous intracapsular hemorrhage of a giant hepatic cavernous hemangioma: a rare case report and literature review. 61
33622256 2021
30
Atypic large hepatic cyst with persistent elevated CA19.9 serum value: utility of intracystic CA72.4 dosage for a mini-invasive management. 61
33216317 2021
31
Ovarian seromucinous cystadenomas and adenofibromas: first report of a case series. 61
32810322 2021
32
Intraductal Papillary Neoplasm of the Bile Duct: A Rare Case of Intrahepatic Space-Occupying Lesion. 61
33680605 2021
33
Characterization and clinical significance of the CADM1/HER2/STAT3 axis in serous ovarian tumors. 61
33663040 2021
34
The expression and significance of leukemia inhibitory factor, interleukin-6 and vascular endothelial growth factor in Chinese patients with endometriosis. 61
33555431 2021
35
Müllerian Mucinous Cystadenomas of the Ovary: A Report of 25 Cases of an Unheralded Benign Ovarian Neoplasm Often Associated With Endometriosis and a Brief Consideration of Neoplasms Arising From the Latter. 61
33577227 2021
36
Cystic lymphangioma of the hepatoduodenal ligament: a rare intra-abdominal tumor mimicking hematoma. 61
32996113 2021
37
Blunt abdominal trauma resulting in ovarian mucinous cystadenoma rupture. 61
32510752 2021
38
Stromal Endocrine Cell Micronests Associated With an Ovarian Mucinous Cystadenoma: Endocrine Cell Preservation (Pseudohyperplasia) Potentially Mimicking Stromal Sex Cord Proliferation or Tumor Microinvasion. 61
31688244 2021
39
Pulmonary Mucinous Cystadenoma - A Rare Pathology. 61
33402519 2021
40
Microcystic pattern and shadowing are independent predictors of ovarian borderline tumors and cystadenofibromas in ultrasound. 61
32780208 2021
41
Microwave ablation of hepatic cyst: A case report. 61
33363720 2021
42
Triple threat: pancreatic cystic lesion presenting with spontaneous hemorrhage is found to harbor three distinct neoplasms. 61
33451339 2021
43
Contemporary Management of Hepatic Cyst Disease: Techniques and Outcomes at a Tertiary Hepatobiliary Center. 61
33083858 2021
44
A rare cause of postmenopausal hyperandrogenism. 61
33414114 2021
45
Determining the significance of psammoma bodies in pelvic washings: A 10-year retrospective review. 61
32931128 2021
46
High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target. 61
33635867 2021
47
Ovarian mucinous cystadenoma with a mural nodule of osteosarcoma: A case report. 61
33494987 2021
48
An intrapancreatic bronchogenic cyst simulating a mucinous cystadenoma. A case report. 61
33267599 2020
49
A Collision between Cavernous-Capillary Hemangioma with Stromal Luteinization and Serous Cystadenoma. 61
33415926 2020
50
A case of multiple serous cystadenoma of pancreas. 61
33299562 2020

Variations for Cystadenoma

Expression for Cystadenoma

Search GEO for disease gene expression data for Cystadenoma.

Pathways for Cystadenoma

GO Terms for Cystadenoma

Cellular components related to Cystadenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 SERPINA3 MUC6 MUC5AC MUC16 MUC1 INHA
2 extracellular region GO:0005576 9.36 SERPINA3 REG4 PTEN MUC6 MUC5AC MUC16
3 Golgi lumen GO:0005796 9.26 MUC6 MUC5AC MUC16 MUC1

Biological processes related to Cystadenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.26 MUC6 MUC5AC MUC16 MUC1
2 ovulation from ovarian follicle GO:0001542 9.16 PGR AFP
3 O-glycan processing GO:0016266 8.92 MUC6 MUC5AC MUC16 MUC1

Sources for Cystadenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....